UKCapital Intelligence Plans
← Company directory

Later stage / growth

Nuclera

Synthetic biology / protein & antibody engineering hardware

VerifiedSeries CCambridge
Companies House
08663936
GLEIF LEI
Not matched
Latest evidence
2026-01-01
Evidence snapshot
2026-09-03
Funding signal2

Dated disclosed rounds · latest 2026-01-01

Procurement signal0

Exact award notices · latest No exact award match

Registry observationMatched

2026-07-01

Regional contextEast

Jun 2026

Signals organise dated evidence; they do not score growth, revenue, creditworthiness or investment performance.

Evidence timeline

4 dated observations

Funding, procurement, registry and identifier records are placed on one chronology. Each row says whether it is a source fact, a record observation or reference metadata; no inferred event is inserted.

  1. RegistryRecord observation

    Status observed: Active

    Snapshot evidence only; this row does not claim the status changed on this date.

  2. FundingSource fact

    Series C extension

    $12M additional (Series C total $87M) · 4 named investors

    Nuclera ↗funding_id joined to resolved canonical company · published
  3. FundingSource fact

    Series C

    $75M · 9 named investors

  4. RegistryRegistry fact

    Company incorporated

    NUCLERA LTD · company 08663936

Latest disclosed round

Series C

Date
2026-01-01
Amount
USD 87m
Sector
Biotech & techbio
Companies House
08663936
ONS region
East

Evidence status

Directory ready

Identity
Verified
Match
High — exact company number and aligned registered name
Operating status
active
Data origins
Core directory, Growth Network, Live Chris T D1

Capital network

5 linked investors

Lead, participant, lender and other retained roles remain distinct where the source supports them. Every relationship below names its source layer, observation date, match method and publication state.

Elevage Medical TechnologiesleadJonathan MilnerleadBritish Business BankparticipantCambridge Innovation CapitalparticipantGK Gohparticipant
InvestorRoleDateSourceMatch / state
Elevage Medical Technologieslead2026-01-01Nuclera ↗ · Vc ↗reviewed canonical company and investor alias resolutiondocumented · published
Jonathan Milnerlead2026-01-01Nuclera ↗ · Vc ↗reviewed canonical company and investor alias resolutiondocumented · published
British Business Bankparticipant2026-01-01Nuclera ↗ · Vc ↗reviewed canonical company and investor alias resolutiondocumented · published
Cambridge Innovation Capitalparticipant2026-01-01Nuclera ↗ · Vc ↗reviewed canonical company and investor alias resolutiondocumented · published
GK Gohparticipant2026-01-01Nuclera ↗ · Vc ↗reviewed canonical company and investor alias resolutiondocumented · published

Funding record

2 disclosed rounds

Open a dated round to move directly between the company, named investors and source publication.

DateStageAmountInvestorsNamed sources
2026-01-13Series C extension$12M additional (Series C total $87M)Elevage Medical Technologies · Jonathan Milner · British Patient Capital · GK GohNuclera ↗
2024-10-16Series C$75MElevage Medical Technologies · British Patient Capital · Cambridge Innovation Capital · GK Goh · M&G Catalyst · Verve Ventures · 3 additional source-listed namesNuclera ↗ · Vc ↗

Companies House status and filing snapshot

NUCLERA LTD

Exact company-number match from the public register. The retained status is active. Filing dates and SIC codes are registry context, not a credit or investment-quality assessment.

Registered record

Status
Active
Company type
Private Limited Company
Country of origin
United Kingdom
Incorporated
2013-08-27
Dissolved
Not applicable
Company number
08663936

Filing context

Accounts category
GROUP
Accounts made up to
2024-12-31
Next accounts due
2026-09-30
Confirmation made up to
2025-08-27
Registry snapshot
2026-07-01
Live check
Bulk snapshot only

Former registered names: NUCLERA NUCLEICS LTD

72110Research and experimental development on biotechnology

SourceCompanies HouseDate2026-07-01Matchexact Companies House numberStatepublished projection

Companies House ↗Registry report →

Traceability

Source trail

Funding and investor claims retain named public-source links. This is a dated research snapshot, not a live cap table.